To,

May 29, 2026

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

ISIN: INE0PLQ01011

Sub: Outcome of the Board Meeting held on Friday, 29th May, 2026

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 29, 2026, inter-alia considered and approved the followings:

1. Audited Standalone and Consolidated Financial Results for half year and year ended March 31, 2026. Pursuant to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the following:

   (a) Statement of Audited Standalone and Consolidated Financial Results for the half year and year ended March 31, 2026.

   (b) Audit Reports, issued by Statutory Auditors of the Company, on the Audited Financial Results of the Company for the half year and year ended March 31, 2026.

   (c) A confirmation pursuant to regulation 33(3) (d) of SEBI (LODR) Regulations 2015 from the CFO of the Company, declaring that the statutory auditors have expressed an unmodified audit opinion in respect of financial results.

2. Appointment of M/s. R P V & Company (FRN: 0134844W), Chartered Accountants as the Internal Auditor of the Company for the financial year 2026-27.

3. Re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Practicing Company Secretaries (Firm Registration No. L2025GJ019100 / Peer Review Certificate No. 6787/2025) as Secretarial Auditor of the Company for the financial year 2026-27.

4. Took note of the resignation of Dr. Pranav Rohitbhai Thaker (DIN: 07602708) from the position of Whole-time Director of the Company w.e.f. the closure of business hours on 25th May, 2026.

5. Redemption of 90,000 6% Non-Convertible Cumulative Redeemable Preference Shares

The particulars / details with respect to re-appointment of Secretarial Auditor and Appointment Internal Auditor of the Company as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed as **Annexure A**.

The aforesaid Board Meeting commenced at 03:00 p.m. (IST) and concluded at 04:20 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

SURANA KASHISH Digitally signed by SURANA KASHISH Date: 2026.05.29 16:43:16 +05'30'

Kashish Surana
Company Secretary & Compliance Officer
ACS- 76674

Encl. as above

Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:
ACURA
& Affiliates
Approved CA Network
Presence in :-
Bengaluru, Delhi, Mumbai, Chennai, Kolkata, Pune, Hyderabad, Patna, Mysuru, Khagaria, Belgavi, Tirupur, Jaipur, Kurnool, **Surat**, Ahmedabad, Vellore & Burdwan

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

1. We have audited the financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated balance sheet as at 31st March 2026, and the Consolidated statement of profit and loss, the Consolidated Statement of Changes in Equity, Consolidated statement of cash flows for the period then ended, and notes to the Consolidated financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

2. The Holding Company's Board of Directors are responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, ('the act') that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are

SAHERWALA & CO. SURAT Chartered Accountants reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid;

Auditor's Responsibility

3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the consolidated financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness

SAHERWALA & CO * Chartered Accountants * SURAT of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March 2026, and their consolidated ~~profit~~/loss and their consolidated cash flows for the period ended on that date.

7. As described in the notes no 1.13 to the financial statements statutory auditor of WOS Maitrya Lifescience Private Limited has qualified his report that. the MLPL Company has not complied with the requirements of Section 55 of the Companies Act, 2013 and the accounting principles generally accepted in India in the preparation and presentation of these financial statements, resulting in material misstatements whose effects are material but not pervasive to the financial statements. These matters collectively form the basis for our Qualified Opinion in accordance with SA 705 (Revised).

Report on Other Legal and Regulatory Requirements

7. According to the information and explanations given to us, and based on the reports, issued by the auditors of the subsidiaries included in the consolidated financial statements of the Company, to which reporting on matters specified in paragraph 3 and 4 of the Order is applicable, provided to us by the Management of the Company and based on the identification of matters of qualifications or adverse remarks in their Companies (Auditor's Report) Order, 2020 reports by

the respective component auditors and provided to us, we report that the auditors of such companies have not reported any qualifications or adverse remarks in their CARO reports.

8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;

d) in our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors of the Holding Company as on 31st March, 2026 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, incorporated in India, none of the directors of the Group companies, incorporated in India is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

i. The Company does not have any legal pending court litigations which would impact its financial position of the Group; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 32.24 to the Balance Sheet)

ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;

iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

PLACE: SURAT
DATE: 29/05/2026

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 26122386UPBQFR5710

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

(₹ in Lakhs)

	Particulars	Half Year ended			For the year ended	
		March 31, 2026	September 30, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from operations	2,115.06	2,369.93	2,229.92	4,484.99	4,666.20
II	Other income	75.73	22.98	38.23	98.71	57.22
III	**Total Revenue (I + II)**	2,190.79	2,392.91	2,268.15	4583.70	4,723.42
IV	**Expenses:**					
	(a) Cost of Raw Material Consumed	259.46	213.65	128.11	473.11	287.17
	(b) Purchase of Stock-in-Trade	220.54	257.92	329.49	478.46	591.39
	(c) Changes in inventories of stock-in-trade	0.71	4.14	7.14	4.85	(2.40)
	(d) Employee benefits expense	285.92	270.57	329.31	556.49	612.78
	(e) Finance costs	105.51	42.89	35.11	148.40	80.20
	(f) Depreciation and amortization expense	73.14	79.06	83.54	152.20	149.64
	(g) Other expenses	1,485.90	1,519.61	1,280.37	3,005.51	2,689.12
	Total Expenses	2,431.18	2,387.84	2,178.79	4,819.02	4,407.83
V	**Profit before prior-period items and tax (III - IV)**	(240.39)	5.07	89.36	(235.32)	315.59
VI	**Prior-Period Items**	11.79			11.79	
VII	**Profit before tax (V- VI)**	(252.18)	5.07	89.36	(247.11)	315.59
VIII	**Tax expense:**					
	(1) Current tax expense	-7.29	7.29	24.89	-	82.72
	(2) Deferred tax expense/(credit)	4.37	1.39	-0.52	5.76	0.63
	(3) Short/(Excess) provision of tax for earlier years	-6.34	-	50.42	(6.34)	50.42
		(9.26)	8.68	74.79	(0.58)	133.78
IX	**Profit from continuing operations (VII-VIII)**	(242.92)	(3.61)	14.57	(246.53)	181.81
X	**Minority Interest**					
XI	**Profit attributable to owners of the equity (IX-X)**	(242.92)	(3.61)	14.57	(246.53)	181.81
XII	**Paid-up Equity Share Capital (Face Value of ₹ 10/- each)**	677.6	677.60	677.60	677.60	677.60
XIII	**Reserves excluding revaluation reserves as per balance sheet of previous accounting year**					
XIV	**Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each**					
	(Pre-bonus)					
	- Basic - Diluted	-3.59	-0.05	0.22	-3.64	2.68
	(Post-bonus)					
	- Basic					
	- Diluted					

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN: 26122386UPBQFR5910

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M.No- A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CONSOLIDATED AUDITED BALANCE SHEET AS ON 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

		CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	**Note No.**	**As at 31st March 2026**	**As at 31st March 2025**
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	174775	199428
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	7480	8227
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	4	219396	36348
b)Deffered tax liability (Net)	5	8064	7034
c)Other long term Liablities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	6	11786	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7		3295
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		40110	28867
c) Other curent Liabilites	8	107260	51805
d) Short term Provisions	9		8272
Total		684395	479943
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Gross Block	10	490270	219621
(ii) Depreciation		82128	67024
(iii) Net Block		408142	152597
b) Non Current Investments	11	10	10
c) Deffered tax asset (net)			
d) Long term loans and advances	12	29622	30489
e) Other Non current assets	13	12946	18442
(2) Current assets			
a) Current Investments	14	522	422
b) Inventories	15	8436	5923
c) Trade receivables	16	110212	149565
d) Cash & Cash equivalents	17	86496	79163
e) Short-term loans and advances	18	23429	39789
f) Other current assets	19	4379	3542
Total		684395	479943

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN : 26122386UPBQFR57ID

For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M.NO - A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Audited Cash Flow Statement for the year ended 31st March 2026
CIN No. - U24290GJ2015PTC107298
(Currency: Rs in '000')

PARTICULARS		CONSOLIDATED AMOUNT As at 31st March 2026	CONSOLIDATED AMOUNT As at 31st March 2025
A. Cash Flow from Operating Activities:			
Net Profit before tax		-23533	32102
Adjustments for :			
Depreciation		15220	14421
Interest Income		4864	2154
Interest & Finance Charges Paid		13630	7984
Gratuity			1677
Profit on sale of Investment			225
Prior Period Adjustment - gst		-725	
Reversal of Previous Year Income Tax		634	
Profit on sale of Fixed Assets		-20	
	Sub Total	23876	22153
Operating Profit before Working Capital Changes		343	54255
Adjustments for :			
Increase / Decrease in Inventories		-2513	147
Increase / Decrease in Short-term loans and advances		1225	-3478
Increase / Decrease in Trade Receivables		44129	-18444
Increase / Decrease in Trade Payables		-785	6571
Increase / Decrease in Other Current Assets		15009	-619
Increase / Decrease in Other Non Current Assets		342	4174
Increase / Decrease in Long-term loans and advances		-19246	145
Increase/Decrease in Provision		-8300	-3918
Increase/Decrease in short term liabilites		-3957	2143
Increase/Decrease in Current Liability		59438	24289
	Sub Total	85344	11000
Cash Generated from Operations		85686	65264
Direct Taxes Paid (Net)		1203	14695
Net Cash inflow in Operating Activities **Total A**		84484	50568
B. Cash Flow from Investing Activities:			
Purchases of Property, Plant and Equipment		-272483	-23813
Purchase of Investment		-100	-44656
Depreciation reveresed back on sale of fixed assets			
Capital Government Grant of Property, Plant and Equipment			
Loans given to Associates and Subsidiaries			
Loans given to Others		-1471	-9073
Loans received from Holding componay			
Interest Income		4864	-2621
Sale of Fixed Assets		1738	2154
Sale of investment		100	4300
		-267351	-73709
Net Cash used in Investing Activities **Total B**		-267351	-73709
C. Cash Flow from Financing Activities:			
Issue of Equity Capital		3900	
Share application Money		-100	51600
Share Premium			
Dividend			
Proceed of Borrowing		12895	4783
Issue of Preference Shares			
Redemption of Preference shares		-10047	-2000
Repayment of Borrowing		197383	-9665
Interest & Finance Charges Paid		-13630	-7984
		190401	36735
Net Cash from Financing Activities **Total C**		190401	36735
Net increase /(decrease) in cash and cash equivalents (A+B+C)		7534	13594
Opening Cash and Cash equivalents		79163	65569
Closing Cash and Cash equivalents		86696	79163

Notes:

(i) Figures in brackets represent outflow. -108.37

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents ... bank balances.

As Per Our Report of Even Date Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN: 26122386UPBQFR5710

Kashish Surana
M.No - A76674
Company Secretary

For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 00084590C7
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited consolidated financial results

1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 29, 2026.

2 The Results for the half year and year ended March 31, 2026 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 The results includes results of 1 wholly owned subsidiaries - Maitreya Lifescience Private Limited and 2 subsidiary - Maitreya Hospital Private Limited and Tulip Agility Private Limited.

4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

5 The figures for the half year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The figures for the half-year ended March 31, 2026 are balancing figure between unaudited figures in respect of the half year ended september 30, 2025 limited reveiwed by the statutory auditors and audited figures for the financial year ended March 31, 2026 .The figures for the half-year ended September 30, 2025 are unaudited published figures in respect of the half-year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The comparative results for the year ended March 31, 2026 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2026 are audited published figures in respect of the year ended March 31, 2026 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

8 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

9 During the preceding year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

SAHERWALA & CO.
SURAT
Chartered Accountants

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited consolidated financial results

10 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till MARCH 31, 2026 (₹ in Thousands)	Amount unutilised till MARCH 31, 2026 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat	75,000.00	75,000.00	-	
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	Remaining amount is kept with banks.
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
	Total	148,912.00	148,512.00	400.00	

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN: 26122386UPBQFR5710

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M.NO - A76174
Company Secretary